Clinical trials
Placebo clinical trials
Below are recruiting placebo clinical trials, each written for real people, not researchers. We’re tracking 5,220 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06138743RecruitingPhase 1/Phase 2
Investigational treatment for adult-onset myotonic dystrophy type 1
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
Liverpool, New South WalesAges 18–65 - NCT07757087RecruitingPhase 1
Study on energy use after weight loss
This study tests a new medicine to see how it affects the body's energy use after losing weight. It compares the medicine to a low-calorie diet or a placebo (a pill with no active ingredient) in adults with obesity.
Aarhus NAges 18 years+ - NCT07758920RecruitingPhase 2
New tablet for long-term shingles pain
This trial tests a new tablet called HL-1186 for treating post-herpetic neuralgia (long-lasting pain after shingles). It compares the new drug to pregabalin, a standard treatment, to see if it's safer and more effective.
BeijingAges 18 years+ - NCT07405801RecruitingPhase 2
Inavolisib plus ribociclib plus fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Anaheim, CaliforniaAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Anchorage, AlaskaAges 18 years+ - NCT07598708RecruitingPhase 2/Phase 3
Cleminorexton for Narcolepsy: A New Treatment Study
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
Colorado Springs, ColoradoAges 18–70 - NCT07013474RecruitingPhase 3
Study of ibuzatrelvir for immunocompromised adults with COVID-19
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
Canoga Park, CaliforniaAges 18 years+ - NCT07755410RecruitingPhase 2
Investigational ADHD treatment for adults
This study tests an investigational medication for adults with attention deficit hyperactivity disorder (ADHD). It aims to see if this new drug helps reduce ADHD symptoms compared to a placebo.
Chino, CaliforniaAges 18–65 - NCT06548204RecruitingPhase 2
Antihistamine after a heart attack
This trial tests whether taking an antihistamine medicine called fexofenadine hydrochloride can help people recover better after a heart attack. It is a randomized study, so some participants will receive the medicine and others will receive a placebo (a pill with no active ingredients).
Hangzhou, ZhejiangAges 18 years+ - NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Scottsdale, ArizonaAges 1–25 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Birmingham, AlabamaAges 18 years+ - NCT06660394RecruitingPhase 3
LP352 for Dravet syndrome in children and adults
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
Little Rock, ArkansasAges 2–65 - NCT05714085RecruitingPhase 2/Phase 3
Vericiguat study for children with heart failure
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Los Angeles, CaliforniaAges 4 weeks–17 years - NCT07668388RecruitingPhase 2
Testing different doses of UBT251 for type 2 diabetes
This trial tests a new medicine, UBT251, to see how well it lowers blood sugar in people with type 2 diabetes. It compares different doses to find the best one for you.
Birmingham, AlabamaAges 18–75 - NCT07271186RecruitingPhase 2
Study of a New Drug for Diabetic Kidney Disease
This study tests an investigational drug that blocks a protein called ANGPTL3, which may help protect the kidneys in people with type 2 diabetes and diabetic kidney disease. It aims to see if the drug can reduce kidney damage and improve overall health.
Huntsville, AlabamaAges 18–80 - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07686679RecruitingPhase 4
A study of DA-9701 for functional dyspepsia
This trial tests a drug called DA-9701 to see if it can help people with functional dyspepsia, a condition where you have stomach pain or discomfort without a clear physical cause. It aims to improve your digestive symptoms.
SeoulAges 19–75 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT07156201RecruitingPhase 1
Safety study of oral ABS-1230 in healthy adults
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
Sydney, New South WalesAges 18–55 - NCT07684820RecruitingPhase 2
A study of ExPD-101 for COPD with chronic bronchitis and frequent flare-ups
This study tests an experimental drug (ExPD-101) given daily as a pill for 52 weeks for people with COPD who have chronic bronchitis and frequent flare-ups. It compares the drug to a placebo (inactive pill) to see if it reduces flare-ups and improves symptoms.
Phoenix, ArizonaAges 40–85 - NCT06920004RecruitingPhase 3
Testing empasiprubart vs IVIg for chronic CIDP
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Birmingham, AlabamaAges 18 years+ - NCT07060638RecruitingPhase 2
Combination therapy for severe alcoholic hepatitis
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
Indianapolis, IndianaAges 18–70 - NCT06850454RecruitingPhase 3
Olanzapine vs placebo for nausea from first chemo
This study tests if the drug olanzapine (commonly used for nausea) can help prevent vomiting in people receiving moderately strong chemotherapy for the first time. It may be a good fit if you're about to start treatment with oxaliplatin, irinotecan, or carboplatin and haven't had severe nausea treatments before.
Bangkok, BangkokAges 18 years+ - NCT06619860RecruitingPhase 2
VX-993 for diabetic nerve pain
This trial tests a new medicine called VX-993 for people with diabetes who have had nerve pain in both feet or legs for at least a year. The goal is to see if it reduces pain and is safe.
Cullman, AlabamaAges 18–80
Hear when a new Placebo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo?
- Yes. Clin2 currently lists 5,220 recruiting placebo studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.